New anthrax vaccine under review for Post-Exposure protection
NCT ID NCT07268612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will look at 250 people who received the CYFENDUS anthrax vaccine after being exposed to anthrax bacteria during a mass event. Researchers want to see if the vaccine, given along with antibiotics, can prevent inhalational anthrax and anthrax meningitis. The study is observational, meaning it will analyze data from past events rather than testing the vaccine in a new controlled experiment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CYFENDUS anthrax vaccine
- What this could lead to
- If this study shows the vaccine works well, it could confirm a safe and effective way to prevent anthrax after a large-scale exposure.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. The study is small and only looks at past events, so it cannot prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2035
An estimate. Start dates often move.
- Expected to finish
-
Nov 2037
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include adults for which CYFENDUS is indicated (18 to 65 years of age), but it may include pediatric, pregnant, and geriatric populations if they are vaccinated with CYFENDUS based on public health recommendations as part of outbreak management.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Individuals who received any dose of CYFENDUS vaccine (with or without concurrent recommended antibacterial regimen) for anthrax post exposure prophylaxis during an identified mass B. anthracis exposure event in the United States. Exclusion Criteria: * Individuals who did not receive CYFENDUS for anthrax post exposure prophylaxis during an identified mass B. anthracis exposure event in the United States.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anthrax are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.